- Home
- BNC vs PBYI Comparison
BNC vs PBYI Comparison
Compare BNC & PBYI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BNC | PBYI |
|---|---|---|
| Founded | N/A | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 287.3M | 343.9M |
| IPO Year | N/A | 2011 |
Fundamental Metrics
Financial Performance| Metric | BNC | PBYI |
|---|---|---|
| Price | $2.63 | $7.24 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 194.7K | ★ 263.1K |
| Earning Date | 05-14-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.61 |
| Revenue | N/A | ★ $27,685,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ $0.22 | $12.26 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.39 | $2.75 |
| 52 Week High | $31.62 | $7.90 |
Technical Indicators
Market Signals| Indicator | BNC | PBYI |
|---|---|---|
| Relative Strength Index (RSI) | 36.77 | 58.03 |
| Support Level | $2.39 | $5.75 |
| Resistance Level | $3.05 | $7.25 |
| Average True Range (ATR) | 0.21 | 0.34 |
| MACD | 0.05 | 0.07 |
| Stochastic Oscillator | 43.19 | 64.79 |
Price Performance
Historical ComparisonAbout BNC CEA Industries Inc.
CEA Industries Inc through its subsidiary is focused on selling environmental control and other technologies and services to the Controlled Environment Agriculture ("CEA") industry. The company provides integrated mechanical, electrical, and plumbing ("MEP") engineering design, proprietary and curated environmental control equipment, and automation offerings that serve the CEA industry. The Company has one operating segment that is dedicated to the manufacture and sale of its products.
About PBYI Puma Biotechnology Inc
Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes inventive products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also, it is developing Alisertib, a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis, resulting in apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.